Critical Limb Ischemia - Pipeline Review, H2 2016

Publication ID: GMD1116023
Publication Date: November 16, 2016
Pages: 145
Publisher: Global Markets Direct
Countries: Global

$2,000.00

Publication License Type *

- SINGLE USER LICENSE (PDF), $2,000.00
- SITE LICENSE (PDF), $4,000.00
- GLOBAL LICENSE (PDF), $6,000.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.
Critical Limb Ischemia - Pipeline Review, H2 2016

Summary


Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Critical Limb Ischemia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Critical Limb Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 11, 4, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages...
comprises 1 molecules, respectively.

Critical Limb Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Critical Limb Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Critical Limb Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Critical Limb Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Critical Limb Ischemia (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Critical Limb Ischemia (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Critical Limb Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

**Table Of Contents:**

- Table of Contents
- Table of Contents 2
- List of Tables 7
- List of Figures 8
- Introduction 9
- Global Markets Direct Report Coverage 9
- Critical Limb Ischemia Overview 10
- Therapeutics Development 11
- Pipeline Products for Critical Limb Ischemia - Overview 11
- Pipeline Products for Critical Limb Ischemia - Comparative Analysis 12
- Critical Limb Ischemia - Therapeutics under Development by Companies 13
- Critical Limb Ischemia - Therapeutics under Investigation by Universities/Institutes 15
- Critical Limb Ischemia - Pipeline Products Glance 16
- Late Stage Products 16
- Clinical Stage Products 17
- Early Stage Products 18
- Critical Limb Ischemia - Products under Development by Companies 19
- Critical Limb Ischemia - Products under Investigation by Universities/Institutes 21
- Critical Limb Ischemia - Companies Involved in Therapeutics Development 22
- AnGes MG, Inc. 22
- Apceth GmbH & Co. KG 23
- Athersys, Inc. 24
- BiogenCell Ltd. 25
- Caladrius Biosciences Inc 26
- Cynata Therapeutics Limited 27
- Hemostemix Ltd 28
- Histocell S.L. 29
ID Pharma Co., Ltd. 30
Integene International Holdings LLC 31
Juventas Therapeutics, Inc. 32
Kasiak Research Private Limited 33
Kowa Company, Ltd. 34
Neurofx, Inc. 35
Pharmicell Co., Ltd. 36
Pluristem Therapeutics Inc. 37
ReNeuron Group Plc 38
Symic Biomedical, Inc. 39
Targzyme, Inc. 40
TikoMed AB 41
U.S. Stem Cell, Inc. 42
Vericel Corporation 43
VESSL Therapeutics Ltd 44
ViroMed Co Ltd 45
Critical Limb Ischemia - Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Target 47
Assessment by Mechanism of Action 49
Assessment by Route of Administration 51
Assessment by Molecule Type 53
Drug Profiles 55
ACP-01 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
AdipoCell - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Alecmestencel-T - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
ASCT-01 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
BC-1 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
beperminogene perplasmid - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
Biologic to Activate FGF2 for Critical Limb Ischemia - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Cellgram-CLI - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
CLBS-12 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
DVC-10101 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
FAB-117HC - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Gene Therapy for Critical Limb Ischemia - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
ixmyelocel-T - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
JVS-100 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
MultiGeneAngio - Drug Profile 88
Stem Cell Therapy for Cardiovascular Diseases and Asthma - Drug Profile 119
Product Description 119
Mechanism Of Action 119
R&D Progress 119
Stem Cell Therapy for Critical Limb Ischemia - Drug Profile 121
Product Description 121
Mechanism Of Action 121
R&D Progress 121
Stem Cell Therapy for Critical Limb Ischemia - Drug Profile 122
Product Description 122
Mechanism Of Action 122
R&D Progress 122
TM-700 - Drug Profile 123
Product Description 123
Mechanism Of Action 123
R&D Progress 123
TXA-302 - Drug Profile 124
Product Description 124
Mechanism Of Action 124
R&D Progress 124
TZ-101 - Drug Profile 125
Product Description 125
Mechanism Of Action 125
R&D Progress 125
VM-202 - Drug Profile 128
Product Description 128
Mechanism Of Action 128
R&D Progress 128
Critical Limb Ischemia - Dormant Projects 132
Critical Limb Ischemia - Discontinued Products 134
Critical Limb Ischemia - Product Development Milestones 135
Featured News & Press Releases 135
Oct 03, 2016: Hemostemix Announces it has been Granted two Additional Patents in the US and in Canada 135
Jun 20, 2016: AnGes Announces Amendment to the Global Development of HGF Plasmid for Critical Limb Ischemia 135
Apr 18, 2016: Hemostemix Receives IRB Approval from the Houston Methodist Hospital Research Institute and the University of California Los Angeles 136
Apr 18, 2016: Caladrius Reaches Agreement with Japanese Regulators on Development Plan for CD34 Cell Therapy for Critical Limb Ischemia 137
Companies Mentioned:

AnGes MG, Inc.
Apceth GmbH & Co. KG
Athersys, Inc.
BiogenCell Ltd.
Caladrius Biosciences Inc
Cynata Therapeutics Limited
Hemostemix Ltd
Histocell S.L.
ID Pharma Co., Ltd.
Integene International Holdings LLC
Juventas Therapeutics, Inc.
Kasiak Research Private Limited
Kowa Company, Ltd.
Neurofx, Inc.
Pharmicell Co., Ltd.
Pluristem Therapeutics Inc.
ReNeuron Group Plc
Symic Biomedical, Inc.
Targazyme, Inc.
TikoMed AB
U.S. Stem Cell, Inc.
Vericel Corporation
VESSL Therapeutics Ltd
ViroMed Co Ltd

License Types:
Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.